(Q33184946)

23 July 2017

title

Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass (English)

1 reference

heparin-induced thrombocytopenia

23 July 2017

1 reference

1 reference

1 reference

1 reference

Hong Liu

1

1 reference

23 July 2017

Neal W Fleming

series ordinal

2

1 reference

23 July 2017

Peter G Moore

series ordinal

3

1 reference

23 July 2017

publication date

1 September 2002

1 reference

Journal of Clinical Anesthesia

23 July 2017

published in

1 reference

23 July 2017

volume

14

1 reference

23 July 2017

issue

6

1 reference

23 July 2017

page(s)

452-455

1 reference

Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Serious bleeding in a haemodialysis patient treated with recombinant hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-8180%2802%2900386-0

7 January 2021

10.1016/S0952-8180(02)00386-0

Identifiers

DOI

1 reference

23 July 2017

1 reference